Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP vaccine in a preclinical model of HER-2 positive breast cancer

• DOI: 10.1016/j.ejca.2024.113822
• Publication Date: 2024-03-22T15:10:29Z
• Authors: F. Ruzzi; L. Scalambra; M.S. Semprini; O.M. Pittino; C. Cappello; S. Angelicola; A. Palladini; P. Nanni; C. Fougeroux; L. Goksøyr; A.F. Sander; P.L. Lollini
• Keywords: Kexin; Proprotein Convertases; PCSK9; Subtilisin; Virus-like particle